Effects of interleukin-10 on neonatal excitotoxic brain lesions in mice
Interleukin-10 markedly reduces production of proinflammatory cytokines by activated microglia or macrophages and downregulates the expression of activating molecules on these cells. In studies performed in adults or in cell cultures, interleukin-10 protected against hypoxic–ischemic neuronal death...
Gespeichert in:
Veröffentlicht in: | Brain research. Developmental brain research 2003-03, Vol.141 (1), p.25-32 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 32 |
---|---|
container_issue | 1 |
container_start_page | 25 |
container_title | Brain research. Developmental brain research |
container_volume | 141 |
creator | Mesples, Bettina Plaisant, Frank Gressens, Pierre |
description | Interleukin-10 markedly reduces production of proinflammatory cytokines by activated microglia or macrophages and downregulates the expression of activating molecules on these cells. In studies performed in adults or in cell cultures, interleukin-10 protected against hypoxic–ischemic neuronal death and against lipopolysaccharide-mediated oligodendrocyte cell death. Furthermore, it was recently shown that interleukin-10 counteracts metabolic and microcirculatory effects of hypoxia–ischemia in the perinatal pig brain. Intracerebral injection of the glutamatergic analogue ibotenate to newborn mice induces cortical plate and white matter lesions mimicking the brain damage associated with cerebral palsy, and pretreatment with proinflammatory cytokines such as interleukin-1-beta or with interleukin-9 significantly exacerbates these lesions. The present study evaluated the influence of interleukin-10 on ibotenate-induced brain lesions in newborn mice under basal conditions or after exposure to cytokines. Intraperitoneal injection of interleukin-10 for 3 days following ibotenate significantly reduced the size of excitotoxic brain lesions. Intraperitoneal injection of neutralizing anti-interleukin-10 antibody for 3 days following ibotenate had no detectable effect and no difference in ibotenate-induced brain lesion size was found between wild type pups and pups deleted for the interleukin-10 gene, suggesting that endogenous interleukin-10 in newborn mice may have limited effects. Co-administration of intracerebral ibotenate and interleukin-10 had no detectable effect, arguing against a direct neuroprotective effect of interleukin-10 on neurons. While pretreatment with intraperitoneal interleukin-10 alone had no detectable effect on excitotoxic brain lesions, interleukin-10 given with interleukin-1-beta pretreatment blunted the toxic effects of interleukin-1-beta. On the other hand, combined pretreatment with IL-9 and anti-IL-10 antibody largely reversed the exacerbating effect of IL-9 on excitotoxic brain lesions. Altogether, these data suggest that, in newborn mice, exogenous interleukin-10 can be neuroprotective when acting in an inflammatory context. |
doi_str_mv | 10.1016/S0165-3806(02)00636-3 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_18729638</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165380602006363</els_id><sourcerecordid>18729638</sourcerecordid><originalsourceid>FETCH-LOGICAL-c444t-5db588b124276145e193896a08b20774bfb0749cb602adfe89a1c6c46c6a04a53</originalsourceid><addsrcrecordid>eNqFkE9PwyAYhzlo3Jx-BA0no4cqUErpyZhlTpMlHtQzAfo2QdsyoTXz24vbokcvvAl5fu-fB6EzSq4poeLmOT1FlksiLgm7IkTkIssP0PT3e4KOY3wjhNBc0iM0oUxwzngxRctF04AdIvYNdv0AoYXx3fUZJdj3uAff60G3GDbWDX7wG2exCdr1uIXofB9TCHfOwgk6bHQb4XRfZ-j1fvEyf8hWT8vH-d0qs5zzIStqU0hpKOOsFJQXQKtcVkITaRgpS24aQ0peWSMI03UDstLUCsuFTQzXRT5DF7u-6-A_RoiD6ly00LY67TpGRWXJKpHLBBY70AYfY4BGrYPrdPhSlKgfa2prTf3oUYSprTWVp9z5fsBoOqj_UntlCbjdAZDO_HQQVLQOegu1C8mkqr37Z8Q3pqB9Gg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>18729638</pqid></control><display><type>article</type><title>Effects of interleukin-10 on neonatal excitotoxic brain lesions in mice</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Mesples, Bettina ; Plaisant, Frank ; Gressens, Pierre</creator><creatorcontrib>Mesples, Bettina ; Plaisant, Frank ; Gressens, Pierre</creatorcontrib><description>Interleukin-10 markedly reduces production of proinflammatory cytokines by activated microglia or macrophages and downregulates the expression of activating molecules on these cells. In studies performed in adults or in cell cultures, interleukin-10 protected against hypoxic–ischemic neuronal death and against lipopolysaccharide-mediated oligodendrocyte cell death. Furthermore, it was recently shown that interleukin-10 counteracts metabolic and microcirculatory effects of hypoxia–ischemia in the perinatal pig brain. Intracerebral injection of the glutamatergic analogue ibotenate to newborn mice induces cortical plate and white matter lesions mimicking the brain damage associated with cerebral palsy, and pretreatment with proinflammatory cytokines such as interleukin-1-beta or with interleukin-9 significantly exacerbates these lesions. The present study evaluated the influence of interleukin-10 on ibotenate-induced brain lesions in newborn mice under basal conditions or after exposure to cytokines. Intraperitoneal injection of interleukin-10 for 3 days following ibotenate significantly reduced the size of excitotoxic brain lesions. Intraperitoneal injection of neutralizing anti-interleukin-10 antibody for 3 days following ibotenate had no detectable effect and no difference in ibotenate-induced brain lesion size was found between wild type pups and pups deleted for the interleukin-10 gene, suggesting that endogenous interleukin-10 in newborn mice may have limited effects. Co-administration of intracerebral ibotenate and interleukin-10 had no detectable effect, arguing against a direct neuroprotective effect of interleukin-10 on neurons. While pretreatment with intraperitoneal interleukin-10 alone had no detectable effect on excitotoxic brain lesions, interleukin-10 given with interleukin-1-beta pretreatment blunted the toxic effects of interleukin-1-beta. On the other hand, combined pretreatment with IL-9 and anti-IL-10 antibody largely reversed the exacerbating effect of IL-9 on excitotoxic brain lesions. Altogether, these data suggest that, in newborn mice, exogenous interleukin-10 can be neuroprotective when acting in an inflammatory context.</description><identifier>ISSN: 0165-3806</identifier><identifier>DOI: 10.1016/S0165-3806(02)00636-3</identifier><identifier>PMID: 12644245</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Animals ; Animals, Newborn ; Cell Death - drug effects ; Cell Death - genetics ; Cerebral Cortex - drug effects ; Cerebral Cortex - pathology ; Cerebral Cortex - physiopathology ; Cerebral palsy ; Cerebral Palsy - drug therapy ; Cerebral Palsy - immunology ; Cerebral Palsy - metabolism ; Drug Interactions - physiology ; Encephalitis - drug therapy ; Encephalitis - immunology ; Encephalitis - metabolism ; Excitotoxicity ; Female ; Ibotenic Acid - antagonists & inhibitors ; Interleukin-1 - pharmacology ; Interleukin-1-beta ; Interleukin-10 - deficiency ; Interleukin-10 - genetics ; Interleukin-10 - pharmacology ; Interleukin-9 - pharmacology ; Interleukin-g ; Male ; Mice ; Mice, Inbred C57BL ; Mice, Knockout ; Microglia ; Microglia - drug effects ; Microglia - immunology ; Microglia - metabolism ; N-Methyl- d-aspartate ; Nerve Degeneration - drug therapy ; Nerve Degeneration - immunology ; Nerve Degeneration - metabolism ; Nerve Fibers, Myelinated - drug effects ; Nerve Fibers, Myelinated - immunology ; Nerve Fibers, Myelinated - metabolism ; Neurotoxins - antagonists & inhibitors ; Survival Rate</subject><ispartof>Brain research. Developmental brain research, 2003-03, Vol.141 (1), p.25-32</ispartof><rights>2002 Elsevier Science B.V.</rights><rights>Copyright 2002 Elsevier Science B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c444t-5db588b124276145e193896a08b20774bfb0749cb602adfe89a1c6c46c6a04a53</citedby><cites>FETCH-LOGICAL-c444t-5db588b124276145e193896a08b20774bfb0749cb602adfe89a1c6c46c6a04a53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12644245$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mesples, Bettina</creatorcontrib><creatorcontrib>Plaisant, Frank</creatorcontrib><creatorcontrib>Gressens, Pierre</creatorcontrib><title>Effects of interleukin-10 on neonatal excitotoxic brain lesions in mice</title><title>Brain research. Developmental brain research</title><addtitle>Brain Res Dev Brain Res</addtitle><description>Interleukin-10 markedly reduces production of proinflammatory cytokines by activated microglia or macrophages and downregulates the expression of activating molecules on these cells. In studies performed in adults or in cell cultures, interleukin-10 protected against hypoxic–ischemic neuronal death and against lipopolysaccharide-mediated oligodendrocyte cell death. Furthermore, it was recently shown that interleukin-10 counteracts metabolic and microcirculatory effects of hypoxia–ischemia in the perinatal pig brain. Intracerebral injection of the glutamatergic analogue ibotenate to newborn mice induces cortical plate and white matter lesions mimicking the brain damage associated with cerebral palsy, and pretreatment with proinflammatory cytokines such as interleukin-1-beta or with interleukin-9 significantly exacerbates these lesions. The present study evaluated the influence of interleukin-10 on ibotenate-induced brain lesions in newborn mice under basal conditions or after exposure to cytokines. Intraperitoneal injection of interleukin-10 for 3 days following ibotenate significantly reduced the size of excitotoxic brain lesions. Intraperitoneal injection of neutralizing anti-interleukin-10 antibody for 3 days following ibotenate had no detectable effect and no difference in ibotenate-induced brain lesion size was found between wild type pups and pups deleted for the interleukin-10 gene, suggesting that endogenous interleukin-10 in newborn mice may have limited effects. Co-administration of intracerebral ibotenate and interleukin-10 had no detectable effect, arguing against a direct neuroprotective effect of interleukin-10 on neurons. While pretreatment with intraperitoneal interleukin-10 alone had no detectable effect on excitotoxic brain lesions, interleukin-10 given with interleukin-1-beta pretreatment blunted the toxic effects of interleukin-1-beta. On the other hand, combined pretreatment with IL-9 and anti-IL-10 antibody largely reversed the exacerbating effect of IL-9 on excitotoxic brain lesions. Altogether, these data suggest that, in newborn mice, exogenous interleukin-10 can be neuroprotective when acting in an inflammatory context.</description><subject>Animals</subject><subject>Animals, Newborn</subject><subject>Cell Death - drug effects</subject><subject>Cell Death - genetics</subject><subject>Cerebral Cortex - drug effects</subject><subject>Cerebral Cortex - pathology</subject><subject>Cerebral Cortex - physiopathology</subject><subject>Cerebral palsy</subject><subject>Cerebral Palsy - drug therapy</subject><subject>Cerebral Palsy - immunology</subject><subject>Cerebral Palsy - metabolism</subject><subject>Drug Interactions - physiology</subject><subject>Encephalitis - drug therapy</subject><subject>Encephalitis - immunology</subject><subject>Encephalitis - metabolism</subject><subject>Excitotoxicity</subject><subject>Female</subject><subject>Ibotenic Acid - antagonists & inhibitors</subject><subject>Interleukin-1 - pharmacology</subject><subject>Interleukin-1-beta</subject><subject>Interleukin-10 - deficiency</subject><subject>Interleukin-10 - genetics</subject><subject>Interleukin-10 - pharmacology</subject><subject>Interleukin-9 - pharmacology</subject><subject>Interleukin-g</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Mice, Knockout</subject><subject>Microglia</subject><subject>Microglia - drug effects</subject><subject>Microglia - immunology</subject><subject>Microglia - metabolism</subject><subject>N-Methyl- d-aspartate</subject><subject>Nerve Degeneration - drug therapy</subject><subject>Nerve Degeneration - immunology</subject><subject>Nerve Degeneration - metabolism</subject><subject>Nerve Fibers, Myelinated - drug effects</subject><subject>Nerve Fibers, Myelinated - immunology</subject><subject>Nerve Fibers, Myelinated - metabolism</subject><subject>Neurotoxins - antagonists & inhibitors</subject><subject>Survival Rate</subject><issn>0165-3806</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE9PwyAYhzlo3Jx-BA0no4cqUErpyZhlTpMlHtQzAfo2QdsyoTXz24vbokcvvAl5fu-fB6EzSq4poeLmOT1FlksiLgm7IkTkIssP0PT3e4KOY3wjhNBc0iM0oUxwzngxRctF04AdIvYNdv0AoYXx3fUZJdj3uAff60G3GDbWDX7wG2exCdr1uIXofB9TCHfOwgk6bHQb4XRfZ-j1fvEyf8hWT8vH-d0qs5zzIStqU0hpKOOsFJQXQKtcVkITaRgpS24aQ0peWSMI03UDstLUCsuFTQzXRT5DF7u-6-A_RoiD6ly00LY67TpGRWXJKpHLBBY70AYfY4BGrYPrdPhSlKgfa2prTf3oUYSprTWVp9z5fsBoOqj_UntlCbjdAZDO_HQQVLQOegu1C8mkqr37Z8Q3pqB9Gg</recordid><startdate>20030314</startdate><enddate>20030314</enddate><creator>Mesples, Bettina</creator><creator>Plaisant, Frank</creator><creator>Gressens, Pierre</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope></search><sort><creationdate>20030314</creationdate><title>Effects of interleukin-10 on neonatal excitotoxic brain lesions in mice</title><author>Mesples, Bettina ; Plaisant, Frank ; Gressens, Pierre</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c444t-5db588b124276145e193896a08b20774bfb0749cb602adfe89a1c6c46c6a04a53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Animals</topic><topic>Animals, Newborn</topic><topic>Cell Death - drug effects</topic><topic>Cell Death - genetics</topic><topic>Cerebral Cortex - drug effects</topic><topic>Cerebral Cortex - pathology</topic><topic>Cerebral Cortex - physiopathology</topic><topic>Cerebral palsy</topic><topic>Cerebral Palsy - drug therapy</topic><topic>Cerebral Palsy - immunology</topic><topic>Cerebral Palsy - metabolism</topic><topic>Drug Interactions - physiology</topic><topic>Encephalitis - drug therapy</topic><topic>Encephalitis - immunology</topic><topic>Encephalitis - metabolism</topic><topic>Excitotoxicity</topic><topic>Female</topic><topic>Ibotenic Acid - antagonists & inhibitors</topic><topic>Interleukin-1 - pharmacology</topic><topic>Interleukin-1-beta</topic><topic>Interleukin-10 - deficiency</topic><topic>Interleukin-10 - genetics</topic><topic>Interleukin-10 - pharmacology</topic><topic>Interleukin-9 - pharmacology</topic><topic>Interleukin-g</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Mice, Knockout</topic><topic>Microglia</topic><topic>Microglia - drug effects</topic><topic>Microglia - immunology</topic><topic>Microglia - metabolism</topic><topic>N-Methyl- d-aspartate</topic><topic>Nerve Degeneration - drug therapy</topic><topic>Nerve Degeneration - immunology</topic><topic>Nerve Degeneration - metabolism</topic><topic>Nerve Fibers, Myelinated - drug effects</topic><topic>Nerve Fibers, Myelinated - immunology</topic><topic>Nerve Fibers, Myelinated - metabolism</topic><topic>Neurotoxins - antagonists & inhibitors</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mesples, Bettina</creatorcontrib><creatorcontrib>Plaisant, Frank</creatorcontrib><creatorcontrib>Gressens, Pierre</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><jtitle>Brain research. Developmental brain research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mesples, Bettina</au><au>Plaisant, Frank</au><au>Gressens, Pierre</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of interleukin-10 on neonatal excitotoxic brain lesions in mice</atitle><jtitle>Brain research. Developmental brain research</jtitle><addtitle>Brain Res Dev Brain Res</addtitle><date>2003-03-14</date><risdate>2003</risdate><volume>141</volume><issue>1</issue><spage>25</spage><epage>32</epage><pages>25-32</pages><issn>0165-3806</issn><abstract>Interleukin-10 markedly reduces production of proinflammatory cytokines by activated microglia or macrophages and downregulates the expression of activating molecules on these cells. In studies performed in adults or in cell cultures, interleukin-10 protected against hypoxic–ischemic neuronal death and against lipopolysaccharide-mediated oligodendrocyte cell death. Furthermore, it was recently shown that interleukin-10 counteracts metabolic and microcirculatory effects of hypoxia–ischemia in the perinatal pig brain. Intracerebral injection of the glutamatergic analogue ibotenate to newborn mice induces cortical plate and white matter lesions mimicking the brain damage associated with cerebral palsy, and pretreatment with proinflammatory cytokines such as interleukin-1-beta or with interleukin-9 significantly exacerbates these lesions. The present study evaluated the influence of interleukin-10 on ibotenate-induced brain lesions in newborn mice under basal conditions or after exposure to cytokines. Intraperitoneal injection of interleukin-10 for 3 days following ibotenate significantly reduced the size of excitotoxic brain lesions. Intraperitoneal injection of neutralizing anti-interleukin-10 antibody for 3 days following ibotenate had no detectable effect and no difference in ibotenate-induced brain lesion size was found between wild type pups and pups deleted for the interleukin-10 gene, suggesting that endogenous interleukin-10 in newborn mice may have limited effects. Co-administration of intracerebral ibotenate and interleukin-10 had no detectable effect, arguing against a direct neuroprotective effect of interleukin-10 on neurons. While pretreatment with intraperitoneal interleukin-10 alone had no detectable effect on excitotoxic brain lesions, interleukin-10 given with interleukin-1-beta pretreatment blunted the toxic effects of interleukin-1-beta. On the other hand, combined pretreatment with IL-9 and anti-IL-10 antibody largely reversed the exacerbating effect of IL-9 on excitotoxic brain lesions. Altogether, these data suggest that, in newborn mice, exogenous interleukin-10 can be neuroprotective when acting in an inflammatory context.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>12644245</pmid><doi>10.1016/S0165-3806(02)00636-3</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0165-3806 |
ispartof | Brain research. Developmental brain research, 2003-03, Vol.141 (1), p.25-32 |
issn | 0165-3806 |
language | eng |
recordid | cdi_proquest_miscellaneous_18729638 |
source | MEDLINE; Alma/SFX Local Collection |
subjects | Animals Animals, Newborn Cell Death - drug effects Cell Death - genetics Cerebral Cortex - drug effects Cerebral Cortex - pathology Cerebral Cortex - physiopathology Cerebral palsy Cerebral Palsy - drug therapy Cerebral Palsy - immunology Cerebral Palsy - metabolism Drug Interactions - physiology Encephalitis - drug therapy Encephalitis - immunology Encephalitis - metabolism Excitotoxicity Female Ibotenic Acid - antagonists & inhibitors Interleukin-1 - pharmacology Interleukin-1-beta Interleukin-10 - deficiency Interleukin-10 - genetics Interleukin-10 - pharmacology Interleukin-9 - pharmacology Interleukin-g Male Mice Mice, Inbred C57BL Mice, Knockout Microglia Microglia - drug effects Microglia - immunology Microglia - metabolism N-Methyl- d-aspartate Nerve Degeneration - drug therapy Nerve Degeneration - immunology Nerve Degeneration - metabolism Nerve Fibers, Myelinated - drug effects Nerve Fibers, Myelinated - immunology Nerve Fibers, Myelinated - metabolism Neurotoxins - antagonists & inhibitors Survival Rate |
title | Effects of interleukin-10 on neonatal excitotoxic brain lesions in mice |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T10%3A59%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20interleukin-10%20on%20neonatal%20excitotoxic%20brain%20lesions%20in%20mice&rft.jtitle=Brain%20research.%20Developmental%20brain%20research&rft.au=Mesples,%20Bettina&rft.date=2003-03-14&rft.volume=141&rft.issue=1&rft.spage=25&rft.epage=32&rft.pages=25-32&rft.issn=0165-3806&rft_id=info:doi/10.1016/S0165-3806(02)00636-3&rft_dat=%3Cproquest_cross%3E18729638%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=18729638&rft_id=info:pmid/12644245&rft_els_id=S0165380602006363&rfr_iscdi=true |